Futibatinib, a potent irreversible pan-FGFR1-4 inhibitor, demonstrated durable activity in the FOENIX-CCA2 study, with an ORR of 41.7%, leading to FDA approval for FGFR2-fusion-positive cholangiocarcinoma [176]. Here, FGFR2 is linked to cholangiocarcinoma.